000303956 001__ 303956
000303956 005__ 20251023094053.0
000303956 0247_ $$2doi$$a10.1002/ijc.70086
000303956 0247_ $$2pmid$$apmid:40827617
000303956 0247_ $$2ISSN$$a0020-7136
000303956 0247_ $$2ISSN$$a1097-0215
000303956 0247_ $$2altmetric$$aaltmetric:180496368
000303956 037__ $$aDKFZ-2025-01731
000303956 041__ $$aEnglish
000303956 082__ $$a610
000303956 1001_ $$0P:(DE-He78)b9e439a1aa1244925f92d547c0919349$$aYuan, Tanwei$$b0$$eFirst author$$udkfz
000303956 245__ $$aMethylation-based alcohol consumption scores as prognostic biomarkers in colorectal cancer: Insights from a population-based cohort.
000303956 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000303956 3367_ $$2DRIVER$$aarticle
000303956 3367_ $$2DataCite$$aOutput Types/Journal article
000303956 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761205212_2347373
000303956 3367_ $$2BibTeX$$aARTICLE
000303956 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303956 3367_ $$00$$2EndNote$$aJournal Article
000303956 500__ $$a#EA:C070#LA:C070# / Volume 157, Issue 12 pp. 2521-2531
000303956 520__ $$aColorectal cancer (CRC) remains a leading cause of cancer-related mortality, with alcohol consumption implicated in its etiology. However, alcohol's prognostic impact on CRC survival is unclear, and self-reported intake is limited by bias. This population-based cohort study evaluated blood DNA methylation-based alcohol scores as objective prognostic tools in 2,129 CRC patients from Germany's DACHS study (2003-2021; median follow-up: 10 years). Participants were recruited from 22 hospitals in Southwest Germany, including non-metastatic (n = 1757) and metastatic (n = 372) patients with complete methylation and alcohol data. All three assessed methylation scores (3-CpG, 450-CpG, 144-CpG) correlated with self-reported lifetime/recent alcohol intake (Spearman's r: 0.29-0.36; p < 0.0001), particularly recent consumption. In non-metastatic patients, self-reported alcohol consumption showed a J-shaped mortality risk, with elevated risks in heavy drinkers and abstainers. A similar dose-response pattern was observed for the 3-CpG methylation score, which showed consistent and robust associations with increased overall mortality (adjusted hazard ratio [aHR] per standard deviation increase: 1.18, 95% CI: 1.11-1.25), non-CRC-related mortality (1.22, 1.13-1.32), and CRC-specific mortality (1.12, 1.00-1.25). The 450-CpG score was associated with overall mortality (1.07, 1.00-1.15), non-CRC-related mortality (1.14, 1.05-1.23), and alcohol consumption-related mortality (1.59, 1.17-2.16). These findings highlight the potential utility of DNA methylation-based alcohol scores, especially the 3-CpG and the 450-CpG scores, as prognostic tools for CRC outcomes. Such biomarkers may provide a more objective measure of alcohol exposure and complement self-reported data in risk stratification and clinical decision-making, though further validation is warranted before clinical implementation.
000303956 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000303956 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303956 650_7 $$2Other$$aDNA methylation
000303956 650_7 $$2Other$$aalcohol consumption
000303956 650_7 $$2Other$$acolorectal cancer
000303956 650_7 $$2Other$$apopulation‐based cohort
000303956 650_7 $$2Other$$aprognosis
000303956 7001_ $$aTagscherer, Katrin E$$b1
000303956 7001_ $$aRoth, Wilfried$$b2
000303956 7001_ $$0P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aBewerunge-Hudler, Melanie$$b3$$udkfz
000303956 7001_ $$aBrobeil, Alexander$$b4
000303956 7001_ $$aKloor, Matthias$$b5
000303956 7001_ $$aBläker, Hendrik$$b6
000303956 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b7$$udkfz
000303956 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b8$$eLast author$$udkfz
000303956 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.70086$$gp. ijc.70086$$n12$$p2521-2531$$tInternational journal of cancer$$v157$$x0020-7136$$y2025
000303956 909CO $$ooai:inrepo02.dkfz.de:303956$$pVDB
000303956 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b9e439a1aa1244925f92d547c0919349$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000303956 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7999346780553d7fab7ba69d5afdfa71$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000303956 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000303956 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000303956 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000303956 9141_ $$y2025
000303956 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000303956 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000303956 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000303956 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000303956 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000303956 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000303956 9201_ $$0I:(DE-He78)W110-20160331$$kW110$$lMicroarrays$$x1
000303956 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000303956 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000303956 980__ $$ajournal
000303956 980__ $$aVDB
000303956 980__ $$aI:(DE-He78)C070-20160331
000303956 980__ $$aI:(DE-He78)W110-20160331
000303956 980__ $$aI:(DE-He78)HD01-20160331
000303956 980__ $$aUNRESTRICTED